September 28, 2004

Seroquel - More data for Bipolar Disorder

UK pharmaceutical manufacturer AstraZeneca has released another set of data demonstrating the benefits of using its drug Seroquel (quetiapine fumarate) for the treatment of bipolar disorder, according to Reuters.

Seroquel is primarily indicated for the treatment of schizophrenia, but has shown an ability to provide relief from symptoms of rapid-cycling bipolar disorder, a form of the central nervous system (CNS) disease that affects around one in five bipolar disorder patients.

Seroquel was found to relieve depressive symptoms among patients over an eight-week period, with significant improvements recorded after the first week of treatment when compared to placebo use.

Many drug companies that sell schizophrenia drugs are now seeking additional approval for the treatment of bipolar disorder to increase sales.

For more of the Seroquel marketing speal - see:

Seroquel is significantly more effective than placebo in treating patients with rapid-cycling bipolar disorder


Post a comment

Type the characters you see in the picture above.

Remember Me?